gastric or gastro-oesophageal junction cancer (advanced)
Description Results

Trial	Studied treatment	Control treatment	patients	ROB	Result	NCT
immune checkpoint inhibition
nivolumab
ATTRACTION-2, 2017	nivolumab	placebo		Low risk of bias	Suggesting	NCT02267343
pembrolizumab
KEYNOTE-059	pembrolizumab	nil			-	NCT02335411
Keynote 061, 2018	pembrolizumab	paclitaxel	2L	Risk of bias	Negative	NCT02370498